FORM 4

UNITED STATES SECUF

Washington, D.C. 20549

KI I	IE2	AND EXC	HANGE	COMMIS	2101

OMB APPROVAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

•										
OMB Number:	3235-0287									
Estimated average I	burden									
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Connealy Pamela Ann</u>				2. Issuer Name and Ticker or Trading Symbol Pyxis Oncology, Inc. [PYXS]							(Chec	5. Relationship of Reporting Perso (Check all applicable) Director Officer (give title)				10% Owner			
(Last) (First) (Middle) C/O PYXIS ONCOLOGY, INC. 321 HARRISON AVENUE, 11TH FL. SUITE 1				3. Date of Earliest Transaction (Month/Day/Year) 11/26/2024								Officer (give title Other (specify below) CFO & COO							
(Street) BOSTON MA 02118 (City) (State) (Zip)				4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Indi Line)	·								
				n-Deriva	tive S	Secui	rities	Acq	uired	, Dis	posed of	, or E	Bene	ficially	/ Own	ed			
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day				tion 2A. Deemed Execution Date,			3. Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)) or 5. Amount of			6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)				
									Code	v	Amount	(A) (D)	or P	rice	Transa	ction(s) 3 and 4)			(instr. 4)
Common Stock 11/26/2					2024		P		5,450	A		\$ 2 1		1,115,743			By Trust ⁽¹⁾		
Common Stock 11/26/20					2024		P		83,400	A	\$	1.96(2)	1,199,143		I		By Spouse		
		Та									osed of, convertib				Owne	d			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		De Se (In:	Price of rivative curity str. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Own Forr Dire or In (I) (I	nership	11. Natur of Indired Beneficia Ownersh (Instr. 4)
					Code	v	(A)	(D)	Date Expiration Exercisable Date		Title	Amo or Num of Shar	ber						

Explanation of Responses:

- 1. These shares are held directly by the Personal Def Ben Pln Trust, a revocable trust for which the Reporting Person and their spouse are the trustees.
- 2. The price reported in column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from \$1.93 to \$1.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

/s/ Pamela Connealy

11/27/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.